Compare CVS Health Corp (CVS) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs iShares Self-Driving EV and Tech — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while iShares Self-Driving EV and Tech trades at $33.34 (market cap $264.50M). The key difference: CVS Health Corp is far larger — about 424.5× iShares Self-Driving EV and Tech's market cap, and CVS Health Corp pays a 3.03% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and iShares Self-Driving EV and Tech for 73 Days on average.
| CVS | IDRV | |
|---|---|---|
Market Cap | $112.29B | $264.50M |
Volume | 7,763,676 | 48,021 |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $45.48 |
52-Week Low | $70.08 | $32.68 |
Typical Hold Time | 83 Days | 73 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
IDRV trades at $33.34, down slightly (-0.06%) with a bearish technical signal. Moving averages indicate selling pressure while oscillators remain neutral. The stock faces resistance at $34 and support at $33. Recent news highlights mixed EV market conditions with strong European demand but weaker US adoption following subsidy changes. Chinese competition and regulatory uncertainties create headwinds for the sector.
The outlook remains cautious given technical weakness and sector challenges. Investment opportunity exists in global EV growth trends, particularly in Europe and China. Key risks include US regulatory uncertainty, Chinese market access restrictions, and volatile oil prices affecting consumer EV adoption decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
